1. Home
  2. GPOR vs BLLN Comparison

GPOR vs BLLN Comparison

Compare GPOR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gulfport Energy Corporation

GPOR

Gulfport Energy Corporation

HOLD

Current Price

$200.13

Market Cap

3.8B

Sector

Energy

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$71.01

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GPOR
BLLN
Founded
1997
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.2B
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
GPOR
BLLN
Price
$200.13
$71.01
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$228.13
$129.57
AVG Volume (30 Days)
367.8K
326.1K
Earning Date
05-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
245.92
N/A
EPS
21.48
N/A
Revenue
$1,422,583,000.00
N/A
Revenue This Year
$17.88
$35.42
Revenue Next Year
$6.71
$32.30
P/E Ratio
$9.15
N/A
Revenue Growth
48.47
N/A
52 Week Low
$153.41
$61.96
52 Week High
$225.78
$138.70

Technical Indicators

Market Signals
Indicator
GPOR
BLLN
Relative Strength Index (RSI) 49.93 42.04
Support Level $199.96 $66.00
Resistance Level $215.65 $100.28
Average True Range (ATR) 7.98 6.53
MACD -1.10 -0.49
Stochastic Oscillator 37.07 34.84

Price Performance

Historical Comparison
GPOR
BLLN

About GPOR Gulfport Energy Corporation

Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: